Trichotillomania: Psychopathological correlates and associations with health-related quality of life in a large sample by Bezerra, Andre P. et al.
1 
 
Trichotillomania --- Psychopathological correlates and associations with health-related 
quality of life in a large sample 
 
Running head: Trichotillomania in a large sample 
 
Andre P. Bezerra1,#; Myrela O. Machado2,#; Michel Maes3,4; Donatella Marazziti5; Paulo R. Nunes-
Neto6; Marco Solmi7; Joseph Firth8,9; M. Ishrat Husain10,11; Andre R. Brunoni12; Paul 
Kurdyak10,11,13; Lee Smith14; Afsaneh Alavi2,15; Vincent Piguet2,15,16; André F. Carvalho10,11,* 
 
 
1Unichristus Medical School, Fortaleza, CE, Brazil; 
2Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada; 
3Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 
4IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, 
Geelong, Victoria, Australia; 
5Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, 
Pisa, Italy; 
6Department of Clinical Medicine, Federal University of Ceara, Fortaleza, CE, Brazil; 
7Department of Neurosciences, University of Padova, Padova, Italy and Padova Neuroscience 
Center, University of Padua, Padua, Italy; 
8 NICM Health Research Institute, Western Sydney University, Westmead, Australia  
9 Division of Psychology and Mental Health, Faculty of Biology, Medicine and Health, University 
of Manchester, Manchester, United Kingdom; 
10Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; 
11Centre for Addiction & Mental Health (CAMH), Toronto, Ontario, Canada; 
12Service of Interdisciplinary Neuromodulation, Laboratory of Neurosciences (LIM-27) and 
National Institute of Biomarkers in Neuropsychiatry (INBioN), Institute of Psychiatry, and 
Department of Clinical Medicine, University of Sao Paulo Medical School, Sao Paulo, Brazil; 
13Institute for Clinical Evaluative Sciences (ICES), Toronto, ON, Canada; 




15Department of Medicine (Dermatology), University of Toronto, Toronto, Ontario, Canada; 
16Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United 
Kingdom. 
#Those authors contributed equally to this manuscript; 
*Corresponding author: 
Andre F. Carvalho, MD, PhD 
Centre for Addiction and Mental Health (CAMH) 
33 Russell Street, Tower Building, T314 
Toronto, ON, Canada, M5S 2S1 





OBJECTIVE: Relatively few studies have assessed the prevalence, correlates, and independent 
impact on quality of life of trichotillomania (TTM) in large samples. 
METHODS: Consecutive participants (N=7,639) were recruited from a cross-sectional web-
based study. Sociodemographic data were collected and several validated self-reported mental 
health measures were completed (Minnesota Impulsive Disorders Interview, Hypomania checklist, 
Fagerström Test for Nicotine Dependence, Alcohol Use Disorders Identification Test, Early 
Trauma Inventory Self Report–Short Form, and the Symptom Checklist-90–Revised Inventory). 
Health-related quality of life (QoL) was assessed with the World Health Organization quality of 
life abbreviated scale (WHOQOL-Bref). Multivariable models adjusted associations to potential 
confounders. 
RESULTS: The sample was predominantly composed of young females (71.3%; mean age: 
27.2±7.9 years). The prevalence of probable TTM was 1.4% (95% CI: 1.2–1.7%), and was more 
common among females. Participants with probable TTM had a greater likelihood of having co-
occurring probable depression (adjusted odds ratio [ORadj]= 1.744; 95% CI: 1.187–2.560), 
tobacco (ORadj = 2.250; 95% CI: 1.191–4.250), and alcohol (ORadj = 1.751; 95% CI: 1.169–
2.621) use disorders. Probable TTM was also independently associated with suicidal ideation 
(ORadj = 1.917; 95% CI: 1.224–3.003) and exposure to childhood sexual abuse (ORadj = 1.221; 
95% CI: 1.098–1.358). In addition, a positive screen for TTM had more impaired physical and 
mental QoL. 
CONCLUSIONS: TTM was associated with a positive screen for several psychiatric 
comorbidities as well as impaired physical and psychological QoL. Efforts towards the recognition 
and treatment of TTM across psycho-dermatology services are warranted. 





Trichotillomania (TTM) or hair-pulling disorder is classified as an obsessive-compulsive spectrum 
disorder according to the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5).1 This chronic condition is characterized by urges to remove one’s body hair leading to 
hair loss. The most common sites reported are the scalp, eyelashes, eyebrows, beard and pubic 
hair.2 Those suffering from TTM often report feelings of unattractiveness, humiliation, and low 
self-confidence.3 
 Patients with TTM most often seek care at dermatology and psychodermatology services, 
and the management of this disorder is a clinical challenge.2,4 Relatively few studies on the 
epidemiology of TTM have been conducted, and the exact prevalence of this disorder in the 
community remains unclear but appears to range from 1-3% with a marked predominance among 
females.5 Most studies have been conducted in clinical settings or otherwise have enrolled 
convenience samples (e.g. university students), and suggest that TTM may be associated with 
several psychiatric comorbidities including depression and anxiety.2,6 In addition, the independent 
impact of TTM on health-related quality of life (QoL) has been a matter of debate with a study 
reporting no impact of TTM on QoL relative to healthy controls,7 whilst two other studies verified 
that people with TTM may have more impaired QoL than non-psychiatric controls.8,9 Moreover, 
the impact of TTM on different QoL domains remains largely unknown.   
The present study aims to: (1) investigate the prevalence of TTM in a large Brazilian 
sample; (2) provide an extensive characterization of sociodemographic and psychopathological 






Study design and participants 
Consecutive participants (N =9,603) were recruited from a large online survey in Brazil, which is 
a project that aims to investigate the prevalence and correlates of several diseases and 
psychopathological conditions using validated self-reported measures. Methodological details of 
this large cross-sectional study are provided elsewhere.10-12 Online surveys have been previously 
adopted to estimate the prevalence and correlates of psychiatric conditions.13,14 To access this 
survey, participants had to be 18 years old or older.  
Potential participants were all individuals living in Brazil who had Internet access. No 
incentives were granted for participation in this survey. Numerous questions to assess 
attention/validation were employed throughout to assess data quality.  Participants who did not 
provide valid responses to these questions were excluded from analyses.  
From the initial sample, 7,639 participants were eligible (i.e., provided correct responses 
to the validation/attention questions) and were included in final analyses (response rate: 79.7%). 
There were no significant differences in background sociodemographic variables between 
participants who were eligible compared to those excluded from analyses (data available upon 
request). 
This online survey collected sociodemographic data and included several validated self-
reported instruments (see below). 
Measures 
Minnesota Impulsive Disorders Interview (MIDI) 
The MIDI is a 36-item semi-structured interview that screens for several disorders including 
pathological gambling, trichotillomania, kleptomania, pyromania, intermittent explosive disorder, 
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compulsive buying, and compulsive sexual behavior. The presence of each disorder is initially 
assessed with a general question, which if answered affirmatively, allows the interviewer to 
respond to other questions. The TTM module comprises a 6-item tool and a positive screening is 
established if all questions are answered affirmatively.15 This 6-item questionnaire was translated 
to Brazilian Portuguese, then back translated into English. Two bilingual authors (MOM and AFC) 
compared the back-translated version to the original version of the MIDI, and modifications to 
ensure semantic equivalence were performed. This Brazilian Portuguese version of the MIDI was 
tested in a pilot sample of 5 outpatients of the psychiatry service of the Walter Cantídio University 
Hospital who reported no difficulties in understanding any of its items. Six experts in the field of 
Obsessive-Compulsive and Related Disorders (OCRDs) provided a qualitative assessment of the 
content validity of the TTM module of the MIDI. In brief, experts were asked to provide comments 
on each item regarding grammar, wording, scaling, and item allocation, as well as the accuracy, 
clarity, style, and relevance of the translation. We calculated the content validity index (CVI) as 
described in detail in previous studies.16,17 To compute the CVI, members of the expert panel were 
asked to rate each MIDI item in terms of relevance, clarity, and simplicity on a Likert scale ranging 
from 1 to 4. The CVI for each item was computed as the number of experts assigning a rate of 3 
or 4 to the item divided by the total number of experts. The overall TTM-MIDI CVI value was 
obtained by averaging all items. The overall CVI of the Brazilian Portuguese version of the TTM-
MIDI was 0.92 (range for individual items: 0.50–1.00), thus supporting its content validity. The 
final Brazilian Portuguese version of the TTM-MIDI is available upon request to the corresponding 
author of this manuscript. The MIDI was considered a positive screen if all questions were 
answered affirmatively. The Cronbach’s alpha of MIDI in the current sample was 0.83 (95% 
confidence interval [CI]: 0.82–0.84) indicating adequate internal consistency reliability. 
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Hypomania checklist (HCL-32)  
The HCL-32 consists of 32 yes/no questions and investigates the presence of hypomanic 
symptoms.18 It also includes 8 severity and functional impact items related to the duration of 
episodes and to positive and negative consequences over different areas of functioning. We used 
the validated Brazilian Portuguese version of the HCL-32 with the recommended cutoff of 19 for 
nonclinical samples.19 For a positive screening for a bipolar spectrum disorder (BD), participants 
had to endorse impairment in at least one area of functioning due to the presence of hypomanic 
symptoms. A previous meta-analysis supports the accuracy of the HCL-32 for the screening of 
BD.20 In the current sample, the reliability of the HCL-32 instrument was adequate (Cronbach’s 
alpha = 0.82; 95% CI: 0.81–0.82).  
Patient Health Questionnaire 9 (PHQ-9)  
We used the validated Brazilian Portuguese version of the PHQ-9 to assess severity of depressive 
symptoms.21,22 A positive screening for major depressive disorder (MDD) was established through 
a previously reported algorithm.21 In addition, we used question 9 of the PHQ-9 to screen for the 
presence of suicidal ideation.23 The Cronbach’s alpha of the PHQ-9 in the current sample was 0.89 
(95% CI: 0.88–0.89). 
Fagerström Test for Nicotine Dependence (FTND)  
DSM-IV nicotine dependence was assessed using the validated Brazilian Portuguese version of 
the FTND,24 a 6-item self-report questionnaire with scores ranging from 0 to 10.25 A cut-off score 
of 4 on the FTND was considered as indicative of nicotine dependence in the current study. The 





Alcohol Use Disorders Identification Test (AUDIT) 
Alcohol use disorder was assessed using the validated Brazilian Portuguese version of the 
AUDIT,26 a 10-item self-report questionnaire developed by the World Health Organization 
(WHO) to screen for the presence of alcoholism.27 A score ≥ 8 was considered indicative of the 
presence of an alcohol use disorder.27 In the current study, the AUDIT had adequate reliability 
(Cronbach’s alpha = 0.83; 95% CI: 0.82–0.83).  
Early Trauma Inventory Self Report–Short Form (ETISR-SF)  
Exposure to early trauma was assessed using the validated Brazilian Portuguese version of the 
ETISR-SF.28 This is self-report inventory comprises 27 items grouped into 4 dimensions (general 
trauma, physical abuse, emotional abuse, and sexual abuse).29 The ETISR-SF exhibited adequate 
internal consistency reliability in the current sample (Cronbach’s alpha = 0.86; 95% CI: 0.86–
0.87).  
Symptom Checklist-90–Revised Inventory (SCL-90R)  
Psychopathological dimensions were assessed using the Brazilian Portuguese version of the 
Symptom Checklist-90–Revised Inventory (SCL-90R).30,31 This is a 90-item, 5-point, Likert-type 
scale, which assesses several psychopathological dimensions: somatization, obsessive-
compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid 
ideation, and psychoticism. In this study, Cronbach’s alpha for the SCL-90R dimensions ranged 
from 0.79 (95% CI: 0.79–0.80) for paranoid ideation to 0.92 (95% CI: 0.91–0.92) for the 
depression dimension.  
World Health Organization Quality of Life instrument–Abbreviated version (WHOQOL-BREF) 
We used the validated Brazilian Portuguese version of the WHOQOL-BREF to assess Quality of 
Life (QoL).32. This scale consists of 26 items assessing QoL in four dimensions: physical, 
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psychological, social, and environment QoL33 Each item is rated on a 5-point, Likert-type scale, 
and scores are transformed on a scale from 0 to 100, with higher scores indicating higher QoL. 
Cronbach’s alpha values were 0.80 (95% CI: 0.80–0.81), 0.83 (95% CI: 0.82–0.84), 0.68 (95% CI: 
0.67–0.70), and 0.79 (95% CI: 0.78–0.79) for the physical, psychological, social, and environment 
domains of the WHOQOL-BREF, respectively. 
Ethics 
The website (www.temperamentoesaudemental.org) provided an encrypted and confidential 
source for data collection. The research ethics committee of the Walter Cantídio University 
Hospital approved all research procedures under the protocol number 1.058.252. To access the 
surveys, participants were required to sign a digital informed consent form. 
Statistical analysis 
Sociodemographic and psychopathological variables were compared between participants with 
TTM and those without TTM. Normally distributed continuous variables were compared using 
Student’s t-test for independent samples. Categorical variables were compared using Pearson’s 
chi-square (χ2) or Fisher’s exact tests as appropriate. Different logistic regression models were 
performed with a positive screen for TTM as the dependent variable, and a positive screen for 
MDD, BD, alcohol or tobacco use disorder, trauma, suicidal ideation, as well as SCL-90R 
psychopathological domain scores as independent variables. For the association of TTM and 
psychopathological dimensions, the scores of each SCL-90R domain were entered as continuous 
independent variables in the model. For the association of TTM and suicidal ideation, the PHQ-9 
question 9 response was entered in the model as a categorical variable. For the associations 
between TTM and trauma domains, the scores of each individual ETISR-SF domain were entered 
as continuous independent variables. All other independent variables were categorical. All 
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multivariable models were adjusted for age, sex, occupation, previous use of psychotropic drugs, 
education level, ethnicity and other background variables as indicated. Multivariable models that 
assessed the association of probable TTM and suicidal ideation as well as exposure to early life 
trauma additionally controlled for the presence of a positive screening for MDD, BD, nicotine 
dependence, and alcohol dependence.  
Separate analysis of covariance (ANCOVA) models were built to assess independent 
associations of probable TTM (predictor variable) and each WHOQOL-BREF domain (dependent 
variables). Each model was adjusted by age, sex, occupation, family history of mental disorders, 
previous use of psychotropic drugs, education level, ethnicity, marital status, gross monthly 
income, presence of a positive screening for a major depressive episode, bipolar spectrum disorder, 
a positive screen for suicidal ideation, nicotine dependence, and alcoholism (reflected as a positive 
screening based on the AUDIT). In addition, we estimated effect sizes of statistically significant  
associations of probable TTM and QoL domains with partial eta squared (ηp2); effect sizes were 
regarded as small, medium, and large when 0.01< ηp2<0.06, 0.06 ≤ ηp2<0.14, and ηp2 ≥ 0.14, 
respectively.34 
 The internal consistency reliability of each instrument used in the current study was 
estimated through Cronbach’s alpha coefficients (and 95% CIs). Statistical significance was set at 









Table 1 summarizes the sociodemographic variables of the sample., which was predominantly 
comprised of women (71.3%), with a mean age of 27.2±7.9 years. The prevalence of probable 
TTM was 1.4% (95% CI: 1.2–1.7%). In addition, the prevalence of probable TTM was 
significantly higher among women, with a total prevalence of 1.63% in women, compared to 
0.95% in men (P=0.025). TTM was not associated with other sociodemographic variables. 
<Please insert Table 1 around here> 
Psychopathological Correlates of TTM 
Associations of mental health correlates and a positive screen for TTM are presented in Table 2. 
The presence of probable TTM was independently associated with a positive screen for MDD, 
tobacco use disorder, and alcohol use disorder. Participants with probable TTM were also more 
likely to exhibit suicidal ideation. 
Finally, TTM was independently associated with exposure to childhood sexual abuse, but 
not with general traumatic experiences, psychological abuse, and physical abuse.  
<Please insert Table 2 here> 
Correlation between probable TTM and quality of life domains 
Probable TTM was independently associated with impaired physical and psychological QoL 
(Figure 1). However, the presence of probable TTM was not associated with social and 
environment QoL. All ANCOVA models were statistically significant (adjusted R2 values ranged 
from 0.172 to 0.444). Effect sizes for the adjusted associations of probable TTM and physical 
(ηp2=0.33) and psychological (ηp2=0.44) QoL domains were large.  




To the best of our knowledge, the current study is the largest cross-sectional survey investigating 
the prevalence and correlates of TTM. Previous studies often evaluated TTM only in children and 
young adults, with a reported lifetime prevalence ranging between 0.6% and 2.4%, and a range 
point prevalence between 0.5% and 1.2%.6,35,36 There is a recent online survey study in a non-
clinical sample that presented a point prevalence of 2%.37 Those data are in accordance with our 
findings which found a point prevalence of probable TTM of 1.4% (95% CI: 1.2–1.7%). Previous 
studies have also reported a greater prevalence of TTM among women, with a female to male ratio 
ranging between 1.5:1 and 7:1.6,35,36,38 Our results are consistent with those findings, as 80.9% of 
the participants who had a positive screening for trichotillomania were females. 
The results of the current study show that probable TTM was independently associated 
with a positive screen for MDD, nicotine and alcohol dependence. These findings are consistent 
with previous studies conducted in clinical samples. For instance, although the prevalence of MDD 
has varied across studies (from 12.5% to 48.0%),8,39,40 evidence overall suggests that depression 
is more common amongst patients with TTM than in the general population. These findings have 
clinical relevance, and physicians assessing TTM should consider those co-occurring mental 
health condition to provide a comprehensive treatment plan to those patients.  
The independent associations with probable TTM and nicotine and alcohol use disorders 
merit further discussion. Both nicotine and alcohol use disorders are characterized by the repetitive 
engagement in behaviors that are rewarding, loss of control (spiraling engagement over time), as 
well as persistence despite detrimental consequences to one’s life and overall functioning.41 
Interestingly, the emerging concept of behavioral addictions, indicates that several habit-related 
disorders may share features with addictions. For example, TTM and skin picking disorder may 
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present phenomenological similarities with substance use disorders. For example, TTM is 
associated with impaired control, functional impairment, and persisting engagement in the 
dysfunctional behaviors despite negative consequences.41,42 It was suggested that glutamatergic 
modulation of dopaminergic tone in the nucleus accumbens, and possibly the prefrontal cortex, 
could be a common mechanism underlying both behavioral addictions (e.g., TTM) and substance 
use disorders.41,43,44 To our knowledge, no previous studies assessed the associations of TTM and 
alcohol or nicotine use disorders in large population samples. Thus, our epidemiological findings 
appear to be consistent with this hypothesis. 
Suicidal ideation was also independently associated with probable TTM. To our 
knowledge, no previous studies assessed the association of suicidal ideation among people with 
TTM. Interestingly, this association survived adjustment to meaningful confounders such as the 
presence of co-occurring mental disorders which are known risk factors for suicide (e.g. depression 
and alcohol use disorder).45 Clearly, this clinically relevant finding deserves independent 
replication. 
In our survey, there was an independent association of exposure to sexual abuse in 
childhood and probable TTM. In the clinical study conducted by Ozten, Sayar, Eryilmaz, Kagan, 
Isik, Karamustafalioglu,46 patients with TTM were more likely than healthy controls to endorse 
previous exposure to traumatic events in childhood, such as neglect, abuse, extreme violence as 
well as sexual harassment and intercourse. Our findings also support those of Gershuny, Keuthen, 
Gentes, Russo, Emmott, Jameson, Dougherty, Loh, Jenike47 who found that the prevalence of post-
traumatic stress disorder among patients with TTM may be higher than in the general population. 
Several studies have suggested that trauma may play a role in the etiology of TTM and it has been 
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hypothesized that TTM may develop in some traumatized individuals as a means to cope with 
those overwhelming experiences.46-48 
Probable TTM was also independently associated with impaired physical and 
psychological QoL. Previous studies presented discrepant findings,7-9 which may at least in part 
reflect the enrollment of participants from different settings since our study enrolled participants 
with probable TTM from a non-clinical setting, whilst previous studies were conducted in clinical 
settings. Furthermore, previous studies enrolled relatively small samples. 
Strengths and limitations 
Our findings should be interpreted under the light of certain limitations. Firstly, we enrolled an 
online sample with a predominance of young women that may not be representative of the 
Brazilian general population. Secondly, we did not use validated structured diagnostic interviews 
to confirm diagnoses although we did use validated self-reporting measures and all instruments 
applied in the current study exhibited adequate internal consistency reliabilities. Thirdly, an online 
project such as ours may have attracted a higher proportion of participants with mental disorders, 
thereby overestimating the prevalence of TTM. Finally, the cross-sectional design of our study 
limits us from drawing any causal inferences from the results., Conversely, the large sample size 
and use of validated assessment tools and use of attention/validation questions are strengths of the 
current study. Furthermore, anonymous participation via the internet provides a setting with low 
desirability bias when responding to these assessment tools. This is especially relevant in TTM, 
since previous research shows that patients with such conditions experience a long delay from 
onset of symptoms to treatment initiation, partly due to the shame individuals may experience as 





TTM appears to be a prevalent condition associated with psychiatric comorbidities. The presence 
of probable TTM was also independently associated with exposure to childhood sexual abuse and 
suicidal ideation. In addition, the presence of probable TTM had a strong independent and 
detrimental impact on physical and psychological QoL. Our findings highlight that the early 
recognition and management of TTM (and associated comorbidities), particularly in at-risk 
settings (e.g., dermatological clinics), is warranted. The design of further large-scale 
epidemiological studies is a necessary next step to replicate/refute our findings. 
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Table 1. Sociodemographic characteristics of study participants 
Variable Total (N = 7,639) 
Trichotillomania 
(N = 110) 
No 
Trichotillomania 
(N = 7529) 
P-value 
Age, years (mean ± SD) 27.2 ± 7.9 25.6 ± 6.8 27.2 ± 7.9 0.041c 
Sex     
Female 5,446 (71.3) 89 (80.9)* 5,357 (71.2)** 0.025a 
Male 2,193 (28.7) 21 (19.1)** 2,172 (28.8)*  
Occupation     
Employed 2,768 (36.2) 42 (39.2) 2,726 (35.0) 0.992b 
Unemployed 2,672 (35) 39 (35.5) 2,633 (35.0)  
Housewife 368 (4.8) 5 (4.5) 363 (4.8)  
Retired  36 (0.5) 0 36 (0.5)  
Self-employed 757 (9.9) 9 (8.2) 748 (9.9)  
Other status 1,038 (13.6) 15 (13.6) 1,023 (13.6)  
Family history of mental disorders     
Yes 3,335 (43.7) 52 (47.3) 3,283 (43.6) 0.660b 
No 4,046 (53.0) 54 (49.1) 3,992 (53.0)  
Don’t know (adopted child) 258 (3.4) 4 (3.6) 254 (3.4)  
Previous use of psychotropic drugs N (%)     
Yes, not currently 1177 (15.4) 24 (21.8) 1,153 (15.3) 0.167a 
Yes, currently 808 (10.6) 10 (9.1) 798 (10.6)  
No 5654 (74.0) 76 (69.1) 5,578 (74.1)  
Daily smoking for the last 12 months N (%) 1129 (14.8) 21 (19.1) 1,108 (14.7) 0.199 
Years of education N (%)     
Less than fundamental 86 (1.1) 3 (2.7) 83 (1.1) 0.266b 
Fundamental school 483 (6.3) 6 (5.5) 477 (6.3)  
High school 4,721 (61.8) 72 (65.5) 4,649 (61.7)  
Superior 2,349 (30.8) 29 (26.4) 2,320 (30.8)  
Ethnicity N (%)     
Caucasian 3,459 (45.3) 49 (44.5) 3,410 (45.3) 0.702b 
African American 773 (10.1) 9 (8.2) 764 (10.1)  
Mulattoe 2,958 (38.7) 43 (39.1) 2,915 (38.7)  
Asian 87 (1.1) 1 (0.9) 86 (1.1)  
Other  362 (4.7) 8 (7.3) 354 (4.7)  
Marital status N (%)     
Single 4,849 (63.5) 70 (63.6) 4,779 (63.5) 0.191a 
Married 1,021 (13.4) 10 (9.1) 1,011 (13.4)  
Stable union 787 (10.3) 17 (15.5) 770 (10.2)  
Divorced/Widow 481 (6.3) 4 (3.6) 477 (6.3)  
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Other 501 (6.6) 9 (8.2) 492 (6.5)  
Religion N (%)     
Catholic 2,305 (30.2) 34 (30.9) 2,271 (30.2) 0.670a 
Evangelical (Protestant) 1,864 (24.2) 24 (21.8) 1,840 (24.4)  
Spiritist  619 (8.1) 13 (1.4) 606 (8.0)  
Agnostic 1,203 (15.7) 17 (15.3) 1,186 (15.8)  
Other 1,648 (21.8) 22 (20.0) 1,626 (21.6)  
Gross monthly income N (%)     
Less than US$ 310.00 2,806 (36.7) 42 (38.2) 2,764 (36.7) 0.964a 
Between US$ 310.00 and US$ 931.00 2,549 (33.4) 33 (30.0) 2,516 (33.4)  
Between US$ 931.00 and US$ 1,863.00 736 (9.6) 11 (10.0) 725 (9.6)  
More than US$ 1,863.00  382 (0.5) 6 (0.08) 376 (5.0)  
Unknown / Not informed 1,166 (15.3) 18 (16.4) 1,148 (15.2)  
Positive screening for major depressive episode N (%) 2,201 (28.8) 47 (42.7)* 2,154 (28.6)** < 0.001a 
Positive screening for bipolar spectrum disorder N (%)  572 (7.6) 13 (11.8) 585 (7.7) 0.098a 
Positive screening for nicotine dependence N (%) 459 (6.0) 12 (10.9)* 447 (5.9)** 0.029a 
Positive screening for alcohol abuse N (%) 1,759 (23.0) 37 (33.6)* 1,722 (22.9)** 0.008a 
Positive screening for suicidal ideation N (%) 1,909 (25.0) 49 (44.5)* 1,860 (24.7)** < 0.001a 
a Pearson’s chi-square test; b Fisher’s Exact test; c Independent samples Student’s t test. 
d Refers to an ethnic group of mixed white and black ancestry. 
* Observed was higher than expected in this cell (adjusted residual > 2). 





Table 2. Association of mental health correlates and trichotillomania 
Variable 
 Unadjusted  Adjusteda 
 OR (95% CI) P-valued  OR (95% CI) P-valued 
MDD positive screening (PHQ-9)  1.861 (1.274–2.719) 0.001  1.744 (1.187–2.560) <0.005 
BD positive screening (HCL-32)  1.630 (0.915–2.903) 0.098  1.616 (0.896–2.913) 0.111 
Tobacco use disorder (FTND)  1.940 (1.067–3.529) 0.029  2.250 (1.191–4.250) 0.012 
Alcohol use disorder (AUDIT)  1.709 (1.149–2.541) 0.008  1.751 (1.169–2.621) 0.007 
Suicideb       
Suicidal ideation (PHQ-9)  2.448 (1.678–3.571) < 0.001  1.917 (1.224–3.003) 0.004 
Suicidal symptoms severity (RASS)  1.005 (0.998–1.012) 0.140  1.002 (0.995–1.009) 0.540 
Psychopathological dimensions (SCL-90)c       
Somatization  1.221 (0.850–1.756) 0.280  1.181 (0.811–1.719) 0.385 
Obsessive Compulsive  1.230 (0.836–1.810) 0.294  1.217 (0.826–1.792) 0.321 
Interpersonal sensitivity  0.977 (0.656–1.455) 0.909  0.918 (0.614–1.373) 0.678 
Depression  0.987 (0.647–1.506) 0.950  0.966 (0.630–1.482) 0.874 
Anxiety  0.797 (0.469–1.356) 0.404  0.804 (0.471–1.372) 0.425 
Hostility  1.097 (0.803–1.499) 0.561  1.084 (0.791–1.484) 0.616 
Phobic anxiety  1.135 (0.818–1.576) 0.447  1.115 (0.802–1.550) 0.517 
Paranoid ideation  0.842 (0.577–1.228) 0.371  0.910 (0.619–1.339) 0.633 
Psychoticism  1.496 (0.947–2.363) 0.084  1.536 (0.964–2.446) 0.071 
Trauma (ETISR-SF)b,c       
General trauma  0.970 (0.882–1.067) 0.534  0.970 (0.880–1.070) 0.546 
Physical abuse  1.055 (0.912–1.220) 0.475  1.074 (0.922–1.251) 0.358 
Psychological abuse  1.060 (0.945–1.189) 0.320  1.027 (0.912–1.157) 0.657 
Sexual abuse  1.252 (1.128–1.389) < 0.001  1.221 (1.098–1.358) < 0.001 
Abbreviations: AUDIT =Alcohol Use Disorders Identification Test; BD = Bipolar Disorder; ETISR-SF = Early Trauma Inventory Self Report – Short 
Form); FTND = Fagerström Test for Nicotine Dependence; HCL-32 = Hypomania Checklist; MDD = Major Depressive Disorder; PHQ-9 = Patient 
Health Questionnaire 9; RASS = Risk Assessment Suicidality Scale; SCL-90 = Symptom Checklist 90. 
a Adjusted for age, gender, education, ethnicity, occupation, and history of psychotropic medication use.  
b Adjusted for a positive screening for MDD or BD, and tobacco or alcohol use disorder. 
c Per unit increase in dimension score. 






FIGURE 1. Associations of probable TTM and physical, psychological, social, and environment quality of life as assessed with the 
WHOQOL-BREF. *P<0.05 (separate ANCOVA models adjusted for sociodemographic and psychopathological variables; see the 
Methods section for further details). Scores of WHOQOL-BREF domains are presented as means and 95% CIs. 
 
